For your BRCAmut+ mCRPC patients following
AR-targeted therapy and chemotherapy

RETHINK LIMITS

with Rubraca

Demonstrated
Anti-Tumor Efficacy

44% of patients achieved a response with Rubraca1

See the data
The number 2 in front of a horizontal timeline bar, indicating demonstrated durability

Demonstrated
Durability

Responses ranged from 1.7 months
to ongoing at 24 months1

See the data
Medical shield icon

Well-Established Safety
and Tolerability Profile

The majority of adverse reactions and lab abnormalities were Grades 1 or 21

SEE SAFETY PROFILE
Checklist icon

Rubraca
Resources

Downloadable resources and videos
for your patients and practice

Get resources

BRCA Mutations in mCRPC

More of your prostate cancer
patients may
have a BRCA
mutation than you think2

BRCA mutations
may be present in

12% (~1 in 8)

of patients with mCRPC2

Germline and somatic
BRCA mutations
have near
equal distribution3-5

Pie chart of somatic mutations and germline mutations

Men with BRCAmut+ associated prostate cancer
are known to have a more aggressive disease6

BRCA1 mutations icon

In a retrospective analysis of prostate cancer outcomes in patients with germline BRCA1 or BRCA2 mutations and noncarriers, BRCA carriers had a significantly more aggressive disease than noncarriers6

BRCA metastatic spread icon

BRCA carriers were more likely to present
with a Gleason scorea ≥8, advanced stage disease, nodal involvement, and metastatic spread6

DNA helix mutations icon

Mutations can occur in both the BRCA1 and BRCA2 genes, and both can lead to more aggressive prostate cancer6

To Help Identify mCRPC Patients at
Greater Risk of Their Disease, Test Tumor DNA for Both
Somatic and Germline BRCA Mutations2,4,5

Scientist performing genetic testing with a cotton swab and vial

BRCA Genetic Testing in Prostate Cancer
Can Identify Patients Who May Benefit From
Targeted Treatments1

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommend genetic testing for BRCA1/2 mutations in appropriate prostate cancer patients7

Germline Testing7

Recommended for:

  • All men with high-risk, very high-risk, regional, or metastatic prostate cancer, regardless of family history
  • Men with prostate cancer and a positive or suspicious family cancer history, a personal history of breast cancer, a known familial cancer risk mutation, or Ashkenazi Jewish ancestry

Consider for:

  • Men with intermediate-risk prostate cancer with intraductal/cribriform histology
  • Men with a personal history of exocrine pancreatic, colorectal, gastric, melanoma, upper tract urothelial, glioblastoma, biliary tract, and small intestinal cancer

Somatic Testing7

Recommended for:

  • Men with metastatic prostate cancer

Considered for:

  • Men with regional prostate cancer

Somatic testing may require repetition when prostate cancer progresses after treatment

BRCA mutations can be detected using tests that analyze tissue or circulating tumor DNA from blood1,8

  • It is important to utilize testing that can identify both germline and somatic mutations
  • PARP inhibition has been demonstrated to be an effective treatment approach in various BRCA-mutated cancers1,9

Anti-Tumor Efficacy

A first-in-class, oral therapy for a genetically defined population of patients with BRCAmut+ mCRPC1

See the data
  • aThe Gleason score ranges from 2-10 and is a measure of whether tissue biopsies look more like normal tissue (lower score) or abnormal tissue (higher score). Two tissue biopsies are each graded based on appearance from 1-5 and added together to generate the Gleason score.
  • AR, androgen receptor-directed therapy; BRCA, breast cancer susceptibility gene; BRCAmut+ mCRPC, breast cancer susceptibility gene-positive metastatic castration-resistant prostate cancer; DNA, deoxyribonucleic acid; mCRPC, metastatic castration-resistant prostate cancer; PARP, poly(ADP-ribose) polymerase.

Contact Clovis Oncology

Please fill out the form below to be contacted by a Clovis Oncology representative

*This field is required

*Mandatory

By submitting this form, you agree to allow Clovis Oncology Inc. to collect the information provided and to receive product and disease-state information from Clovis, our affiliates, service providers, and co-promotion partners by phone, email, or mail. Clovis or third-party partners working on our behalf will not sell, rent, or otherwise distribute your name and any personally identifiable information. We may share your information with our partners in accordance with our Terms of Use and Privacy Policy.

The information contained in this website is intended for U.S. healthcare professionals only.

By clicking the button below, you acknowledge that you are a U.S. healthcare professional.